N-methanesulfonyl-4-(aminomethyl)piperidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-methanesulfonyl-4-(aminomethyl)piperidine
• 英文别名: (1-(methylsulfonyl)piperidin-4-yl)methanamine；{[1-(methylsulfonyl)piperidin-4-yl]methyl}amine；(1-Methanesulfonylpiperidin-4-yl)methanamine；(1-methylsulfonylpiperidin-4-yl)methanamine
• 化学式: C₇H₁₆N₂O₂S
• mdl: MFCD10016327
• 分子量: 192.282
• InChiKey: IMGMCBHZBZUFDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-methanesulfonyl-4-(aminomethyl)piperidine 在 titanium(IV) isopropylate 、 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 3-{(1R,4S,6S)-4-[(1-Methanesulfonyl-piperidin-4-ylmethyl)-amino]-bicyclo[4.1.0]hept-1-yl}-benzonitrile
  参考文献：
  名称：

  Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases

  摘要：

  A series of novel aminobenzimidazoles was prepared and evaluated for h-MCH-R1 antagonist properties. Most of the compounds showed excellent h-MCH-R1 binding affinity as well as mouse ex vivo binding. Compounds 9 and 18 were active in mouse DIO studies at 30 mpk. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.07.058

文献信息

• [EN] PYRROLO CARBOXAMIDES AS MODULATORS OF ORPHAN NUCLEAR RECEPTOR RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORϒ, NR1F3) ACTIVITY AND FOR THE TREATMENT OF CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES<br/>[FR] PYRROLOCARBOXAMIDES EN TANT QUE MODULATEURS DE L'ACTIVITÉ D'UN RÉCEPTEUR ORPHELIN GAMMA (RORϒ, NR1F3) APPARENTÉ AU RÉCEPTEUR NUCLÉAIRE ORPHELIN RAR ET DESTINÉS AU TRAITEMENT DE MALADIES INFLAMMATOIRES CHRONIQUES ET AUTO-IMMUNES
  申请人：PHENEX PHARMACEUTICALS AG

  公开号：WO2013079223A1

  公开（公告）日：2013-06-06

  The invention provides modulators for the orphan nuclear receptor RORϒ and methods for treating RORϒ mediated diseases by administrating these novel RORϒ modulators to a human or a mammal in need thereof. Specifically, the present invention provides pyrrolo carboxamide compounds of Formula (1) and the enantiomers, diastereomers, N-oxides, tautomers, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了针对孤儿核受体RORϒ的调节剂，以及通过向需要的人或哺乳动物施用这些新型RORϒ调节剂来治疗RORϒ介导的疾病的方法。具体而言，本发明提供了式(1)的吡咯甲酰胺化合物及其对映体、非对映体、N-氧化物、互变异构体、溶剂化物和药用可接受的盐。
• [EN] HETEROCYCLIC COMPOUNDS WITH AN ROR(GAMMA)T MODULATING ACTIVITY<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES AYANT UNE ACTIVITÉ DE MODULATION DE ROR(GAMMA)T
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2018030550A1

  公开（公告）日：2018-02-15

  The present invention relates to a compound that may have an ROR(gamma)t modulating activity and can thus be useful in the treatment of cancer.

  本发明涉及一种可能具有ROR(gamma)t调节活性的化合物，因此可用于癌症治疗。
• Quinolinone compounds as 5-HT4 receptor agonists
  申请人：Goldblum A. Adam

  公开号：US20060199839A1

  公开（公告）日：2006-09-07

  The invention provides novel quinolinone-carboxamide 5-HT 4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT 4 receptor activity, and processes and intermediates useful for preparing such compounds.

  这项发明提供了新型喹诺酮-羧酰胺5-HT4受体激动剂化合物。该发明还提供了包括这些化合物的药物组合物，使用这些化合物治疗与5-HT4受体活性相关疾病的方法，以及用于制备这些化合物的过程和中间体。
• ISOINDOLINE INHIBITORS OF ROR-GAMMA
  申请人：VITAE PHARMACEUTICALS, INC.

  公开号：US20160122318A1

  公开（公告）日：2016-05-05

  Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

  提供了化合物的新颖结构式（I）：其药用盐，以及其药物组合物，可用于治疗由RORγ介导的疾病和紊乱。还提供了包含新颖结构式（I）化合物的药物组合物，以及它们在治疗一种或多种炎症性、代谢性、自身免疫和其他疾病或紊乱中的使用方法。
• [EN] DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA<br/>[FR] INHIBITEURS DE ROR-GAMMA À BASE DE DIHYDROPYRROLOPYRIDINE
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2015116904A1

  公开（公告）日：2015-08-06

  Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

  提供了化合物的新结构（I）：其药用盐以及药物组合物，可用于治疗由RORγ介导的疾病和紊乱。还提供了包含化合物的新结构（I）的药物组合物以及其在治疗一个或多个炎症、代谢、自身免疫和其他疾病或紊乱中的使用方法。